APAC Hospital Priorities – China Pharma Perspective

Stephen Sunderland

title slide

table of contents

hospital survey respondent mix

private vs public hospital mix

budget outlook for public hospitals

restrictions on sales rep access

hospital spending priorities

innovative drug access

barriers to NRDL drugs

spending through VBP

changes in prescription behavior

cutting back on commercial investment

change in prescription from hospitals

focus areas

value of digital health solutions

top concerns for digital health adoption

adoption of digital tools

disclaimer

thank you

Related Insights

Executive Insights

Life Sciences & Pharma

Transitioning to EU-Wide Health Technology Assessments: Implications for Pharma

April 14, 2025

Life Sciences & Pharma

Optimizing Four-Wall DC Operations for a Pharmaceutical Distributor

March 27, 2025

After years of stable but stagnant warehouse performance, a major pharmaceutical distributor sought to modernize its technology infrastructure to boost…

Video / Webinar

Digital

Driving AI Success: Leadership Strategies from the C-Suite

October 11, 2024

Executive Insights

Life Sciences & Pharma

Oncology BD&L: Winning in an Increasingly Competitive Environment

September 12, 2024

Video / Webinar

Healthcare Services

Global Collaboration Opportunities in China's Healthcare Innovation

August 7, 2024

Video / Webinar

Biotech and Pharmaceuticals

Pharma's Big Shift: From Doctors to Payers Providers and Patients

July 25, 2024